Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Cash from Investing Activities (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Cash from Investing Activities readings, the most recent being $18.9 million for Q2 2017.

  • On a quarterly basis, Cash from Investing Activities rose 270371.43% to $18.9 million in Q2 2017 year-over-year; TTM through Dec 2017 was $23.3 million, a 2325700.0% increase, with the full-year FY2025 number at $10.8 million, up 115.35% from a year prior.
  • Cash from Investing Activities hit $18.9 million in Q2 2017 for Eledon Pharmaceuticals, up from $4.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $18.9 million in Q2 2017 to a low of -$24.3 million in Q2 2015.
  • Median Cash from Investing Activities over the past 5 years was -$9000.0 (2014), compared with a mean of -$1.2 million.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 404816.67% in 2015 and later skyrocketed 270371.43% in 2017.
  • Eledon Pharmaceuticals' Cash from Investing Activities stood at -$4000.0 in 2013, then tumbled by 3825.0% to -$157000.0 in 2014, then tumbled by 101.27% to -$316000.0 in 2015, then surged by 104.11% to $13000.0 in 2016, then skyrocketed by 145538.46% to $18.9 million in 2017.
  • The last three reported values for Cash from Investing Activities were $18.9 million (Q2 2017), $4.3 million (Q1 2017), and $13000.0 (Q4 2016) per Business Quant data.